Loading
A phase 1 trial of JUR-003 run by Juri Biosciences, Inc., now recruiting.
JUR-003 in Adult Patients With Metastatic Prostate Cancer is a phase 1 interventional study registered as NCT07824349 by Juri Biosciences, Inc., with 210 participants planned, started 2026-09. Conditions recorded: Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC) and Metastatic Hormone Sensitive Prostate Cancer. Interventions recorded: JUR-003.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/